

Freedom of Information Act 2000 - Request Reference Fol/21/396
Biologic and Biosimilar Products within Rheumatology

Request Details

Dear Cardiff and Vale University Health Board,

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

| | |
|----------------------------|-----|
| • Abatacept [Orencia] | 44 |
| • Adalimumab [Humira] | 30 |
| • Adalimumab Biosimilars | 199 |
| • Apremilast [Otezla] | 0 |
| • Baricitinib [Olumiant] | 36 |
| • Certolizumab [Cimzia] | 94 |
| • Etanercept [Enbrel] | 24 |
| • Etanercept Biosimilars | 188 |
| • Filgotinib [Jyseleca] | 0 |
| • Golimumab [Simponi] | 32 |
| • Guselkumab [Tremfya] | 0 |
| • Infliximab [Remicade] | 3 |
| • Infliximab Biosimilars | 14 |
| • Ixekizumab [Taltz] | 5 |
| • Risankizumab [Skyrizi] | 0 |
| • Rituximab [MabThera] | 1 |
| • Rituximab Biosimilars | 39 |
| • Sarilumab [Kevzara] | 8 |
| • Secukinumab [Cosentyx] | 29 |
| • Tocilizumab [Ro Actemra] | 98 |
| • Tofacitinib [Xeljanz] | 6 |
| • Upadacitinib [Rinvoq] | 1 |
| • Ustekinumab [Stelara] | 15 |